ABBV stock sentiment todayAbbVie Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
ABBV
AbbVie Inc.AbbVie is successfully navigating the Humira patent cliff through Skyrizi and Rinvoq, but its current valuation reflects much of this optimism.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ABBV. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from 'Humira fear' to 'Immunology growth,' but recent M&A activity (ImmunoGen and Cerevel) has sparked debate over overpayment and long-term pipeline integration.
- ·Robust uptake of Skyrizi and Rinvoq exceeding analyst expectations
- ·Massive M&A spending to bolster oncology and neuroscience pipelines
- ·Concerns over Medicare drug price negotiations (IRA) impact
Financial
Solid cash flow generation supports a top-tier dividend; however, debt levels are elevated due to recent acquisitions and the P/E ratio is trending above its 5-year historical average.
- ·Forward P/E: ~17.5x (Premium compared to historic 12-14x)
- ·Dividend Yield: ~3.1% (Consistent growth)
- ·Operating Margin: ~30-35% (Industry leading efficiency)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $8.2M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Accelerated erosion of Humira revenue as biosimilars gain formulary positioning
- ·Pipeline setbacks in late-stage oncology trials (e.g., ADCs)
- ·Regulatory pressure on pricing for top-selling immunology drugs
Peer temperature
How direct competitors stack up against ABBV right now.
- HOTLLYEli Lilly and Company
HOTTER — capturing massive growth in the GLP-1 (obesity/diabetes) market that dwarfs AbbVie's immunology expansion.
See full analysis → - COLDPFEPfizer Inc.
COLDER — struggling with post-COVID revenue declines and a lack of clear near-term catalysts compared to AbbVie's stable core.
See full analysis → - NEUTRALJNJJohnson & Johnson
STEADIER — offers a cleaner balance sheet and lower volatility, though lacks the aggressive growth potential of Skyrizi.
See full analysis →
- ABBV+12.7%
- LLY+22.5%
- PFE+7.0%
- JNJ+3.2%
Analyst price target
Consensus average of 23 analysts · median 290.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.